Placebo News and Research

RSS

Drug does not appear to reduce risk of heart attack or death following CABG surgery

Use of MC-1 (a naturally occurring metabolite of vitamin B6) before and for 30 days after coronary artery bypass graft surgery did not reduce the risk of heart attack or cardiovascular death, according to a JAMA study being released early online April 1 to coincide with its presentation at the annual conference of the American College of Cardiology.

2 Apr 2008

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics

Results of a randomised trial published in PLoS Medicine show no benefit in cognitive or neuropsychiatric outcomes from continuing neuroleptic drugs in patients with Alzheimer's disease.

1 Apr 2008

Eli Lilly starts trial of treatment of mild to moderate Alzheimer's disease

Eli Lilly and Company has announced the start of a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the treatment of mild to moderate Alzheimer's disease.

1 Apr 2008

Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly

Lowering the blood pressure of elderly patients could cut their total mortality by a fifth and their rate of cardiovascular events by a third, according to a new study presented at the American College of Cardiology in Chicago and published simultaneously in the New England Journal of Medicine.

1 Apr 2008

Hypertension treatment for the elderly cuts the risk of heart disease and stroke

New research from Britain suggests that when the elderly are treated for hypertension (high blood pressure) the medication reduces their risk of heart disease, stroke and even death.

1 Apr 2008

Dieting and medication may reduce blood pressure in patients with hypertension

Adults with hypertension may be able to lower their weight and their blood pressure by following a weight-loss diet or using the medication orlistat, according to a meta-analysis of previously published studies reported in the March 24 issue of Archives of Internal Medicine.

25 Mar 2008

Price of medicine may affect its efficacy

You are offered two painkillers, one selling at full price for $2.50 per pill and the other discounted to 10 cents each.

20 Mar 2008

MedImmune advances clinical development of antibody targeting interleukin-9 in patients with asthma

MedImmune has announced that its clinical program studying an investigational treatment targeting interleukin-9 (IL-9) has advanced with the start of a new trial in patients with asthma.

19 Mar 2008

Only two per cent of 700 paediatric drug trials included independent safety checks

Only two per cent of paediatric drug trials reported that they had established independent safety monitoring committees that can help lead to the early detection of adverse drug reactions, according to a major review in the April issue of Acta Paediatrica.

19 Mar 2008

Pycnogenol improves memory of senior citizens

New research accepted for publication in the Journal of Psychopharmacology, demonstrates Pycnogenol, (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, improves the memory of senior citizens.

18 Mar 2008

Aspirin cuts asthma risk in women

A small dose of aspirin on alternate days can cut the risk of developing asthma among women, suggests a large study, published ahead of print in Thorax.

14 Mar 2008

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

AstraZeneca has announced that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC).

13 Mar 2008

Myostatin shows promise for muscular dystrophy

Myostatin, a protein that blocks muscle growth, has shown promising results as a potential therapeutic target for treating muscular dystrophy in animal studies, where its inhibition led to increased muscle mass and strength.

12 Mar 2008

Low dose inhaled corticosteroids improve lung function in mild asthma patients

A study by the Woolcock Institute of Medical Research in Sydney is the first to demonstrate that in patients with very mild or well-controlled asthma, regular treatment with low dose ICS leads to significantly better day-to-day lung function.

11 Mar 2008

Late treatment with letrozole (Femara) can reduce breast cancer recurrence risk

Treatment with the aromatase inhibitor letrozole (Femara) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy.

11 Mar 2008

Femara helps protect against return of breast cancer after completing Tamoxifen therapy

Women may reduce the risk of their breast cancer returning by starting treatment with Femara (letrozole tablets) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published in the Journal of Clinical Oncology.

11 Mar 2008

Risks of long-term hormone therapy continue to outweigh benefits

New results from the Women's Health Initiative (WHI) confirm that the health risks of long-term use of combination (estrogen plus progestin) hormone therapy in healthy, postmenopausal women persist even a few years after stopping the drugs and clearly outweigh the benefits.

6 Mar 2008

Costly placebo works better than cheap one

A 10-cent pill doesn't kill pain as well as a $2.50 pill, even when they are identical placebos, according to a provocative study by Dan Ariely, a behavioral economist at Duke University.

6 Mar 2008

Cancer risk slightly higher for women in discontinued hormone treatment trial

A follow up study of participants in the Women's Health Initiative (WHI) clinical trial led by a University of North Carolina at Chapel Hill researcher has found that women who were taking the combined hormone therapy of estrogen plus progestin may have an increased risk of cancer since the intervention was stopped, compared to participants in the trial's placebo group.

6 Mar 2008

Cancer risk from HRT remains long after treatment has stopped

The results of a new study have shown that the risk of cancer associated with Hormone Replacement Therapy (HRT) continues long after a woman stops taking it.

5 Mar 2008